Prevention of Persistent Postsurgical Pain After Thoracotomy

NCT01243801 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2015-03-23

No results posted yet for this study

Summary

Postthoracotomy acute pain is followed by persistent postsurgical pain in 20-30% of the patients, defined as pain that lasts more than 3-6 months after surgery. Acute pain and hyperalgesia around the surgical wound are some of the risk factors associated to the development of chronic pain. Ketamine, as a NMDA antagonist mainly at spinal level, might reduce periincisional hyperalgesia and persistent postsurgical pain after thoracotomy. Therefore, the investigators hypothesized that continuous ketamine infusion at subanesthetic dose would potentiate epidural ropivacaine and fentanyl-induced analgesia after thoracotomy, reduce periincisional hyperalgesia and long-term postoperative pain. To test these hypothesis, the investigators administered a low dose of intravenous ketamine or epidural ketamine or placebo to patients who received an epidural infusion of ropivacaine and fentanyl for postthoracotomy pain.

Conditions

  • Persistent Pain
  • Postoperative Hyperalgesia

Interventions

DRUG

Ketamine

Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Beatriz Tena, MD · Hospital Clinic of Barcelona

  • Carmen Gomar, PhD · Hospital Clinic of Barcelona

  • Irene Rovira, PhD · Hospital Clinic of Barcelona

  • Maria J Jimenez, PhD · Hospital Clinic of Barcelona

  • Guillermina Fita, PhD · Hospital Clinic of Barcelona

  • Samuel Garcia, MD · Hospital Clinic of Barcelona

  • Jordi Perez, PhD · Hospital Clinic of Barcelona

  • Daniel Poggio, MD · Hospital Clinic of Barcelona

  • Jose Rios · Hospital Clinic of Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-10-31
Completion
2011-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243801 on ClinicalTrials.gov